These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey. Nielsen ME; Smith AB; Pruthi RS; Guzzo TJ; Amiel G; Shore N; Lotan Y BJU Int; 2012 Oct; 110(7):967-72. PubMed ID: 22487336 [TBL] [Abstract][Full Text] [Related]
44. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115 [TBL] [Abstract][Full Text] [Related]
45. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692 [TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study. Soria F; Milla P; Fiorito C; Pisano F; Sogni F; Di Marco M; Pagliarulo V; Dosio F; Gontero P World J Urol; 2016 Feb; 34(2):189-95. PubMed ID: 26026818 [TBL] [Abstract][Full Text] [Related]
47. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. van Valenberg H; Colombo R; Witjes F Int J Hyperthermia; 2016 Jun; 32(4):351-62. PubMed ID: 26905963 [TBL] [Abstract][Full Text] [Related]
48. A systematic review on the available treatment modalities for Bacillus Calmette-Guérin-unresponsive carcinoma in situ and tumors in patients who are ineligible for or decline radical cystectomy. Syed S; Rahman M; Israr A; Anwar M; Khatroth S; Safi D; Kamran A SAGE Open Med; 2023; 11():20503121231160408. PubMed ID: 36949824 [TBL] [Abstract][Full Text] [Related]
49. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer. Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026 [TBL] [Abstract][Full Text] [Related]
50. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis. Huang Z; Liu H; Wang Y; Zhang C; Xu T Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272 [TBL] [Abstract][Full Text] [Related]
52. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy. Barlow L; McKiernan J; Sawczuk I; Benson M BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012 [TBL] [Abstract][Full Text] [Related]
53. Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer. Bachir BG; Dragomir A; Aprikian AG; Tanguay S; Fairey A; Kulkarni GS; Breau RH; Black PC; Kassouf W Cancer; 2014 Aug; 120(16):2424-31. PubMed ID: 24752448 [TBL] [Abstract][Full Text] [Related]
54. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials. Chen S; Zhang N; Shao J; Wang X Int J Surg; 2018 Apr; 52():248-257. PubMed ID: 29499363 [TBL] [Abstract][Full Text] [Related]
55. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798 [TBL] [Abstract][Full Text] [Related]
56. [Chemohyperthermia using MMC in non-muscle-invasive bladder cancer: Current status and future perspectives.]. Coenen JJMJH; van Valenberg FJP; Arends TJH; Witjes JA Arch Esp Urol; 2018 May; 71(4):400-408. PubMed ID: 29745929 [TBL] [Abstract][Full Text] [Related]
57. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer. Evans CP Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082 [No Abstract] [Full Text] [Related]
58. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729 [TBL] [Abstract][Full Text] [Related]
59. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Duchek M; Johansson R; Jahnson S; Mestad O; Hellström P; Hellsten S; Malmström PU; Eur Urol; 2010 Jan; 57(1):25-31. PubMed ID: 19819617 [TBL] [Abstract][Full Text] [Related]
60. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]